{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T23:47:08Z","timestamp":1792021628005,"version":"4.4.0"},"reference-count":46,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,5,20]],"date-time":"2024-05-20T00:00:00Z","timestamp":1716163200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100017606","name":"Optimum Patient Care","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017606","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jaci-inpractice.org","clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Allergy and Clinical Immunology: In Practice"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.jaip.2024.05.016","type":"journal-article","created":{"date-parts":[[2024,5,19]],"date-time":"2024-05-19T05:17:12Z","timestamp":1716095832000},"page":"2347-2361","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":40,"title":["Exploring Definitions and Predictors of Response to Biologics for Severe Asthma"],"prefix":"10.1016","volume":"12","author":[{"given":"Ghislaine","family":"Scelo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trung N.","family":"Tran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tham T.","family":"Le","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malin","family":"Fager\u00e5s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Delbert","family":"Dorscheid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Busby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mona","family":"Al-Ahmad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riyad","family":"Al-Lehebi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan","family":"Altraja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron","family":"Beastall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celine","family":"Bergeron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leif","family":"Bjermer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne S.","family":"Bjerrum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana Jimena","family":"Cano-Rosales","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgio Walter","family":"Canonica","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Carter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy","family":"Charriot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George C.","family":"Christoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Borja G.","family":"Cosio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eve","family":"Denton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Jose","family":"Fernandez-Sanchez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo\u00e3o A.","family":"Fonseca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter G.","family":"Gibson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celine","family":"Goh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liam G.","family":"Heaney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrico","family":"Heffler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Hew","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Iwanaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rohit","family":"Katial","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariko S.","family":"Koh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piotr","family":"Kuna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D\u00e9sir\u00e9e","family":"Larenas-Linnemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauri","family":"Lehtim\u00e4ki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bassam","family":"Mahboub","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hisako","family":"Matsumoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew N.","family":"Menzies-Gow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolaos G.","family":"Papadopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pujan","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"Perez-De-Llano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Peters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul E.","family":"Pfeffer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Todor A.","family":"Popov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celeste M.","family":"Porsbjerg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chin K.","family":"Rhee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohsen","family":"Sadatsafavi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camille","family":"Taill\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos A.","family":"Torres-Duque","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-Ju","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte S.","family":"Ulrik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John W.","family":"Upham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"von B\u00fclow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eileen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael E.","family":"Wechsler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9728-9992","authenticated-orcid":false,"given":"David B.","family":"Price","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaip.2024.05.016_bib1","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1164\/rccm.201504-0763PP","article-title":"Evolving concepts of asthma","volume":"192","author":"Gauthier","year":"2015","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaip.2024.05.016_bib3","doi-asserted-by":"crossref","first-page":"2680","DOI":"10.1016\/j.jaip.2021.02.059","article-title":"Cluster analysis of inflammatory biomarker expression in the International Severe Asthma Registry","volume":"9","author":"Denton","year":"2021","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2024.05.016_bib4","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.resinv.2023.02.003","article-title":"Evolution of asthma treatment goals","volume":"61","author":"Sakagami","year":"2023","journal-title":"Respir Investig"},{"key":"10.1016\/j.jaip.2024.05.016_bib5","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.jaci.2003.09.008","article-title":"Development of the asthma control test: a survey for assessing asthma control","volume":"113","author":"Nathan","year":"2004","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2024.05.016_bib6","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1034\/j.1399-3003.1999.14d29.x","article-title":"Development and validation of a questionnaire to measure asthma control","volume":"14","author":"Juniper","year":"1999","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jaip.2024.05.016_bib7","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1080\/17476348.2023.2226392","article-title":"Defining response to therapy with biologics in severe asthma: from global evaluation to super response and remission","volume":"17","author":"Papaioannou","year":"2023","journal-title":"Expert Rev Respir Med"},{"key":"10.1016\/j.jaip.2024.05.016_bib8","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1080\/17476348.2023.2223986","article-title":"Criteria to evaluate efficacy of biologics in asthma: a Global Asthma Association survey","volume":"17","author":"Tiotiu","year":"2023","journal-title":"Expert Rev Respir Med"},{"key":"10.1016\/j.jaip.2024.05.016_bib9","doi-asserted-by":"crossref","first-page":"00444","DOI":"10.1183\/23120541.00444-2022","article-title":"Definitions of non-response and response to biological therapy for severe asthma: a systematic review","volume":"9","author":"Khaleva","year":"2023","journal-title":"ERJ Open Res"},{"key":"10.1016\/j.jaip.2024.05.016_bib10","doi-asserted-by":"crossref","first-page":"3997","DOI":"10.1016\/j.jaip.2021.06.041","article-title":"Defining a severe asthma super-responder: findings from a Delphi process","volume":"9","author":"Upham","year":"2021","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2024.05.016_bib11","doi-asserted-by":"crossref","first-page":"2848","DOI":"10.1111\/all.15382","article-title":"RELIght: a two-year REal-LIfe study of mepolizumab in patients with severe eosinophilic asTHma in Greece: evaluating the multiple components of response","volume":"77","author":"Kallieri","year":"2022","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2024.05.016_bib12","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.chest.2020.03.042","article-title":"Real-world effectiveness and the characteristics of a \u201csuper-responder\u201d to mepolizumab in severe eosinophilic asthma","volume":"158","author":"Kavanagh","year":"2020","journal-title":"Chest"},{"key":"10.1016\/j.jaip.2024.05.016_bib13","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.chest.2020.08.2083","article-title":"Real-world effectiveness of benralizumab in severe eosinophilic asthma","volume":"159","author":"Kavanagh","year":"2021","journal-title":"Chest"},{"key":"10.1016\/j.jaip.2024.05.016_bib14","first-page":"1734","volume":"159","author":"Wechsler","year":"2021"},{"key":"10.1016\/j.jaip.2024.05.016_bib15","doi-asserted-by":"crossref","first-page":"2725","DOI":"10.1016\/j.jaip.2021.01.033","article-title":"Development of a tool to measure the clinical response to biologic therapy in uncontrolled severe asthma: the FEV1, exacerbations, oral corticosteroids, symptoms score","volume":"9","author":"P\u00e9rez de Llano","year":"2021","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2024.05.016_bib16","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.chest.2023.10.046","article-title":"Clinical response and remission in severe asthma patients treated with biologic therapies","volume":"165","author":"Hansen","year":"2024","journal-title":"Chest"},{"key":"10.1016\/j.jaip.2024.05.016_bib17","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1016\/j.anai.2023.12.023","article-title":"Impact of pre-biologic impairment on meeting domain-specific responder definitions in patients with severe asthma","volume":"132","author":"Perez de Llano","year":"2024","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaip.2024.05.016_bib18","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2016-011857","article-title":"Impact of omalizumab on treatment of severe allergic asthma in UK clinical practice: a UK multicentre observational study (the APEX II study)","volume":"6","author":"Niven","year":"2016","journal-title":"BMJ Open"},{"key":"10.1016\/j.jaip.2024.05.016_bib19","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1111\/imj.13166","article-title":"Effectiveness and response predictors of omalizumab in a severe allergic asthma population with a high prevalence of comorbidities: the Australian Xolair Registry","volume":"46","author":"Gibson","year":"2016","journal-title":"Intern Med J"},{"key":"10.1016\/j.jaip.2024.05.016_bib20","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1111\/cea.14026","article-title":"Effectiveness of benralizumab in severe eosinophilic asthma: Distinct sub-phenotypes of response identified by cluster analysis","volume":"52","author":"Di Bona","year":"2022","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.jaip.2024.05.016_bib21","doi-asserted-by":"crossref","first-page":"00238","DOI":"10.1183\/23120541.00238-2022","article-title":"Complete response to anti-interleukin-5 biologics in a real-life setting: results from the nationwide Danish Severe Asthma Register","volume":"8","author":"Soendergaard","year":"2022","journal-title":"ERJ Open Res"},{"key":"10.1016\/j.jaip.2024.05.016_bib22","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1080\/00325481.2017.1321945","article-title":"Predictors of response to therapy with omalizumab in patients with severe allergic asthma - a real life study","volume":"129","author":"Kallieri","year":"2017","journal-title":"Postgrad Med"},{"key":"10.1016\/j.jaip.2024.05.016_bib23","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1164\/rccm.201708-1668OC","article-title":"Predicting responders to reslizumab after 16 weeks of treatment using an algorithm derived from clinical studies of patients with severe eosinophilic asthma","volume":"199","author":"Bateman","year":"2019","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaip.2024.05.016_bib24","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1056\/NEJMoa1804092","article-title":"Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma","volume":"378","author":"Castro","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaip.2024.05.016_bib25","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1111\/all.14425","article-title":"EAACI biologicals guidelines: recommendations for severe asthma","volume":"76","author":"Agache","year":"2021","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2024.05.016_bib27","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/j.chest.2019.10.051","article-title":"International Severe Asthma Registry (ISAR): mission statement","volume":"157","year":"2020","journal-title":"Chest"},{"key":"10.1016\/j.jaip.2024.05.016_bib28","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/j.jaip.2018.08.016","article-title":"Development of the International Severe Asthma Registry (ISAR): A Modified Delphi Study","volume":"7","author":"Bulathsinhala","year":"2019","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2024.05.016_bib29","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1186\/s12874-020-01065-0","article-title":"International severe asthma registry (ISAR): protocol for a global registry","volume":"20","author":"FitzGerald","year":"2020","journal-title":"BMC Med Res Methodol"},{"key":"10.1016\/j.jaip.2024.05.016_bib31","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1016\/j.chest.2021.04.013","article-title":"Eosinophilic and non-eosinophilic asthma: an expert consensus framework to characterize phenotypes in a global real-life severe asthma cohort","volume":"160","author":"Heaney","year":"2021","journal-title":"Chest"},{"key":"10.1016\/j.jaip.2024.05.016_bib32","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.anai.2011.09.001","article-title":"Prospective evaluation of current asthma control using ACQ and ACT compared with GINA criteria","volume":"107","author":"Korn","year":"2011","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaip.2024.05.016_bib33","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1183\/09031936.00173710","article-title":"Comparing Global Initiative for Asthma (GINA) criteria with the Childhood Asthma Control Test (C-ACT) and Asthma Control Test (ACT)","volume":"38","author":"Koolen","year":"2011","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jaip.2024.05.016_bib34","doi-asserted-by":"crossref","first-page":"3629","DOI":"10.1016\/j.jaip.2023.07.041","article-title":"Severe Asthma Network Italy definition of clinical remission in severe asthma: a Delphi consensus","volume":"11","author":"Canonica","year":"2023","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2024.05.016_bib35","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00819-2023","article-title":"Clinical remission in severe asthma with biologic therapy: an analysis from the UK Severe Asthma Registry","volume":"62","author":"McDowell","year":"2023","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jaip.2024.05.016_bib37","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1186\/s12931-023-02409-2","article-title":"Can we predict who will benefit most from biologics in severe asthma? A post-hoc analysis of two phase 3 trials","volume":"24","author":"Chen","year":"2023","journal-title":"Respir Res"},{"key":"10.1016\/j.jaip.2024.05.016_bib38","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1111\/all.13302","article-title":"Response to omalizumab using patient enrichment criteria from trials of novel biologics in asthma","volume":"73","author":"Casale","year":"2018","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2024.05.016_bib39","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/S2213-2600(15)00042-9","article-title":"Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials","volume":"3","author":"Castro","year":"2015","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jaip.2024.05.016_bib40","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00936-2018","article-title":"Baseline patient factors impact on the clinical efficacy of benralizumab for severe asthma","volume":"52","author":"Bleecker","year":"2018","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jaip.2024.05.016_bib41","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.pupt.2017.01.011","article-title":"Reslizumab in patients with inadequately controlled late-onset asthma and elevated blood eosinophils","volume":"43","author":"Brusselle","year":"2017","journal-title":"Pulm Pharmacol Ther"},{"key":"10.1016\/j.jaip.2024.05.016_bib42","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1136\/thorax-2021-217032","article-title":"Asthma exacerbations are associated with a decline in lung function: a longitudinal population-based study","volume":"78","author":"Soremekun","year":"2023","journal-title":"Thorax"},{"key":"10.1016\/j.jaip.2024.05.016_bib43","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1164\/rccm.201208-1414OC","article-title":"Exploring the effects of omalizumab in allergic asthma: an analysis of biomarkers in the EXTRA study","volume":"187","author":"Hanania","year":"2013","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaip.2024.05.016_bib44","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/S2213-2600(16)30031-5","article-title":"Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies","volume":"4","author":"Ortega","year":"2016","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jaip.2024.05.016_bib45","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S2213-2600(17)30344-2","article-title":"Predictors of enhanced response with benralizumab for patients with severe asthma: pooled analysis of the SIROCCO and CALIMA studies","volume":"6","author":"FitzGerald","year":"2018","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jaip.2024.05.016_bib46","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.jaip.2018.04.043","article-title":"Omalizumab effectiveness by biomarker status in patients with asthma: evidence from PROSPERO, a prospective real-world study","volume":"7","author":"Casale","year":"2019","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2024.05.016_bib47","article-title":"Personalized evidence based medicine: predictive approaches to heterogeneous treatment effects","volume":"363","author":"Kent","year":"2018","journal-title":"BMJ"},{"key":"10.1016\/j.jaip.2024.05.016_bib48","first-page":"127","article-title":"Adult severe asthma registries: a global and growing inventory","volume":"14","author":"Cushen","year":"2023","journal-title":"Pragmat Obs Res"},{"key":"10.1016\/j.jaip.2024.05.016_bib49","article-title":"Clinical remission following biologic initiation in severe asthma: results of the International Severe Asthma Registry (ISAR)","volume":"62","author":"Scelo","year":"2023","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jaip.2024.05.016_bib50","article-title":"Characteristics associated with clinical remission in patients with severe asthma who initiate biologics","volume":"62","author":"Perez de Llano","year":"2023","journal-title":"Eur Respir J"}],"container-title":["The Journal of Allergy and Clinical Immunology: In Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213219824005300?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213219824005300?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,2]],"date-time":"2024-11-02T04:28:05Z","timestamp":1730521685000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213219824005300"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":46,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["S2213219824005300"],"URL":"https:\/\/doi.org\/10.1016\/j.jaip.2024.05.016","relation":{},"ISSN":["2213-2198"],"issn-type":[{"value":"2213-2198","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Exploring Definitions and Predictors of Response to Biologics for Severe Asthma","name":"articletitle","label":"Article Title"},{"value":"The Journal of Allergy and Clinical Immunology: In Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaip.2024.05.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc. on behalf of the American Academy of Allergy, Asthma & Immunology.","name":"copyright","label":"Copyright"}]}}